New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
February 21, 2025 - The FDA announced the approval of Mirum Pharmaceuticals’ Ctexli (chenodiol), for treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Download PDF
Return to publications
